Project

Challenges: 70% of the world’s population are still out of reach within centralized healthcare system. Although local hospitals have high accessibility, limited level of expertise in diagnostics and treatment leads patents to central hospitals, which causes decrease in service quality.
Solution: Innovative diagnostics platform offering fast and accurate diagnosis at local hospitals and on site is required. NOUL is currently in the process of developing miLab, the next-generation point of care diagnostic laboratory platform providing central hospital-quality diagnosis in a short amount of time at a low cost without specific laboratory facility.

Project Summary

NOUL’s miLab, Miniaturized-Intelligent Laboratory, enables faster and more accurate diagnosis of diseases through development of an all-in-one technology that transfers the entire laboratory into one single portable device. miLab technology is an integration of three core technologies: lab on a chip (LOC), artificial intelligence, and data platform, replacing the laboratory and the technicians. Through the data platform that collects and monitor health data globally, NOUL explores global challenges that threaten human health and life, discover novel potential solutions, and realize those possibilities.

Business Model

[Cumulative Profit Model]
Step 1 (Device): Distribution of diagnostic devices
Step 2 (Diagnostic chip): Sales of consumable diagnostic chips + various kinds of diagnostic chips (up to 150+ diseases)
Step 3 (Data platform): Discovery of new diseases through big data; Sales of the analyzed data to pharmaceutical companies, etc.
Step 4 (B2C): Market expansion to B2C (home use) diagnostics market (e.g., WBC count for patients undergoing chemotherapy, etc)

Main Achievements

2015.12) NOUL Inc. established. Moves into D.Camp.
2016.01) Wins the local round of 1776 Global Startup Challenge Cup (Korea)
2016.02) NOUL corporate research laboratory established
2016.06) Participates as a select innovator at the UN STI Forum (one of the 15 innovators out of 700 global corporations)
2016.07) Graduates from D.Camp and moves the headquarter to Suji U Tower
2016.09) IRB approves clinical trial in Cambodia and Malawi
2016.10) Participates as a representative of Korea at Grand Challenges Annual Meeting 2016 held by Gates Foundation
2016.11) 1st clinical trial in Cambodia takes place
2016.11) Officially registered and certified as a business venture by Gyeonggi Venture Business Association
2017.01) 1st clinical trial in Malawi takes place
2017.02) Signs MoU with Swiss TPH (clinical trial in Tazania)
2017.03) Corporate laboratory moves to a larger facility and establishes production line (Class II bio laboratory)
2017.05) 2nd clinical trial in Malawi takes place
2017.06) Main keynote presentation at the 4th Swiss-Korean Life Science Symposium - Digital Health and Precision Medicine (Basel, Switzerland)
2017.11) Selected as one of the innovative companies by Basel University Bio-innovation Center in Switzerland
2017.12) Signs MoU with FIND Diagnostics (clinical trial partnership)